GlobeNewswire

Compuware Acquires XaTester and Partners with Parasoft to Deliver Essential Automated Unit Testing to Mainframe DevOps Teams

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=63b6178d-f04f-4003-9f2a-fca7ad9a8f2e&maxHeight=150&maxWidth=150

Topaz Further Established as the Leading Solution for Continuously Improving Velocity, Quality and Efficiency of Enterprise Systems

  • Large enterprises must rigorously safeguard the quality of their mission-critical mainframe systems as digital demands drive them to develop and deploy mainframe code more quickly and frequently. 
  • With the acquisition of XaTester, new enhancements, and partnership with Parasoft, Compuware Topaz for Total Test is the clear leader in the automated unit testing essential for Agile and DevOps on the mainframe.
  • With Topaz, developers at all skill levels can quickly and efficiently produce the highest-quality code for the mainframe-enabling enterprises to achieve the digital agility essential for success in fast-moving markets.             

DETROIT, July 18, 2018 (GLOBE NEWSWIRE) -- Compuware today announced a product acquisition, enhancements to Topaz for Total Test, and a partnership that together dramatically improve the ability of large enterprises to embrace Agile and DevOps on their mainframes through the broader use of simplified, automated unit testing-which is essential for fast, safe and efficient development and deployment of new digital deliverables.

To deliver on its vision of Topaz for Total Test as the de facto standard for automating mainframe unit testing across all major mainframe environments and programming languages, Compuware has:

  • Acquired XaTester from Xact Consulting A/S, enabling developers to quickly create unit tests for both batch and CICS-based programs written in COBOL, PL/I and Assembler. CICS is especially important as the transaction processing technology of choice for many of the world's largest enterprises-especially financial institutions and insurance companies-due to its extremely high integrity, performance and scalability.
     
  • Enhanced Topaz for Total Test to provide automated unit testing for IMS batch and transactional applications. Testing for IMS is especially important given that contemporary developers often have little or no hands-on experience with IMS code. These enhancements complement Topaz for Total Test's existing support for batch applications written in COBOL-as well as its integration with leading cross-platform DevOps tools such as Jenkins, SonarSource SonarQube and Compuware ISPW.
     
  • Partnered with Parasoft, a leading innovator in end-to-end test automation for software development. The first deliverable for the partnership is integration between Parasoft SOAtest and Topaz for Total Test. This integration enables developers working on mainframe applications to quickly and easily test API calls between mainframe and non-mainframe systems.

Topaz for Total Test fundamentally transforms mainframe development by giving developers the same type of unit testing capabilities on the mainframe they've become accustomed to on other platforms. Unit testing is a fundamental requirement for modern software development. It enables developers to find potential problems in their code as early as possible, to more quickly and frequently deliver incremental changes in software functionality, and to more granularly document code for the benefit of other developers.

The result for large enterprises is a unified DevOps toolchain that accelerates development across all platforms-including the mainframe-so they can more effectively compete in today's rapidly-changing markets.

"XaTester and Topaz for Total Test are two great and complementary products for automating mainframe unit testing, which is essential to DevOps," said Steen Brahe, Senior Product Manager, Compuware (formerly from Xact Consulting). "The unified tool will leverage the best from both products and fundamentally change how customers create, execute and automate unit and integration tests for mainframe applications."

"The XaTester unit testing software has proven its value. I am pleased that Compuware will work to blend its capabilities with Topaz for Total Test as it will benefit all mainframe customers," said Elvin Høyer, CEO at Xact Consulting.   

"The new rules of the digital economy are putting pressure on our customers to achieve the utmost speed with the utmost quality," said Luke Tuddenham, Vice President at CPT, a global IT consulting services firm with a significant testing practice. "With today's announcements, Compuware has again demonstrated its leadership in innovative automated testing technologies for the mainframe that will help us help our clients to achieve this critical goal."

Compuware Topaz, a comprehensive suite of solutions, provides DevOps professionals at all skill levels with a visually intuitive environment where they can effectively understand and work on any mainframe application-regardless of age, complexity or lack of documentation. This simplified, streamlined approach is especially important as responsibility for applications running on the platform shifts from IT professionals with decades of mainframe-specific experience to a new generation of DevOps artisans who are more familiar with mainstream technologies such as Java and C++.

"REST and SOAP APIs provide the backbone of today's business-critical applications, especially when these services are used to access the power of the mainframe." said Parasoft VP of Products, Mark Lambert. "Test automation at the API layer is essential to delivering high quality at the speed of Agile and the Parasoft SOAtest plugin for Topaz brings API test automation directly to the mainframe developer, helping ensure the delivery of reliable, scalable and secure services."

Today's announcement comes during the 15th consecutive quarter that Compuware has delivered significant innovations that help large enterprises mainstream the mainframe, so they can better leverage the platform's unmatched performance, scalability, reliability, efficiency and security.

"Large enterprises increasingly recognize that digital innovation in the cloud must be paired with digital innovation on the mainframe," said Chris O'Malley, CEO of Compuware. "Compuware's passion and support for this mainframe-based digital innovation is unmatched-as we have once again demonstrated with this latest round of aggressive deliverables that enable Agile and DevOps best practices on the platform."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum